Answers are grounded in this paper and cite their sources.
Purpose: To report initial real-world experience with revakinagene taroretcel for macular telangiectasia type 2 and assess intergrader reproducibility of ellipsoid zone (EZ) loss and a width-based area estimate for eligibility screening. Methods: A retrospective review of 8 eyes of 8 patients who underwent implantation by 3 surgeons was performed. Surgical technique, visual acuity (VA), intraocular pressure (IOP), and complications were recorded through 1 month. Two masked graders independently measured preoperative area of EZ loss on optical coherence tomography raster scans by direct area measurement and estimated area from EZ loss width using a circular model. Agreement was assessed with intraclass correlation coefficients and Bland-Altman analysis. Results: Mean age was 61.5 ± 6.5 years; 7 patients were women; all eyes were phakic and operated under local anesthesia. No intraoperative or serious adverse event occurred, and no eye developed pupillary miosis. Mean VA declined from 0.31 ± 0.11 logMAR (20/41) at baseline to 0.42 ± 0.19 (20/53) at day 1, recovered to 0.31 ± 0.24 (20/41) by week 1, and stabilized at 0.22 ± 0.16 (20/33) by month 1. Intergrader agreement was excellent for both methods (intraclass correlation coefficients, 0.97 and 0.99). The width-based estimate correlated strongly with direct area measurement (r ≥ 0.97) but overestimated it by a mean factor of 1.62. Conclusions: Implantation was feasible and safe through the first postoperative month, and measurement of preoperative EZ loss was highly reproducible. In this small series, the width-based estimate correlated strongly with the directly measured EZ-loss area but systematically overestimated it, suggesting that a correction factor may be needed for rapid eligibility screening.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: